Companies: 49,246 Total Market Cap: 132386205533959.40

Marinomed Biotech AG

VIE-MARI
Healthcare Biotechnology
Rank #34155
Market Cap 25.07 M
Volume 50
Price 14.21
Change (%) 0.80%
Country or region Austria Austria

Marinomed Biotech AG's latest marketcap:

25.07 M

As of 05/20/2025, Marinomed Biotech AG's market capitalization has reached $25.07 M. According to our data, Marinomed Biotech AG is the 34155th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 25.07 M
Revenue (ttm) 5.40 M
Net Income (ttm) -17,385,226.19
Shares Out 1.78 M
EPS (ttm) -9.78
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 09/17/2025
Market Cap Chart
Data Updated: 05/20/2025

Marinomed Biotech AG's yearly market capitalization.

Marinomed Biotech AG has seen its market value drop from €175.25 M to €22.23 M since 2020, representing a total decrease of 87.32% and an annual compound decline rate (CAGR) of 37.53%.
Date Market Cap Change (%)
05/20/2025 €22.23 M -18.33%
12/30/2024 €26.67 M -39.87%
12/29/2023 €44.36 M -47.78%
12/30/2022 €84.95 M -34.78%
12/30/2021 €130.25 M -25.67%
12/30/2020 €175.25 M

Company Profile

About Marinomed Biotech AG

Marinomed Biotech AG is a biopharmaceutical company specializing in therapeutic products for virology and immunology. Headquartered in Korneuburg, Austria, the company operates across Europe and internationally.

Business Segments

The company operates through three key segments:

  • Virology – Focuses on treatments for viral respiratory infections.
  • Immunology – Develops therapies for immune-related conditions.
  • Other – Includes additional research and development initiatives.

Product Pipeline

Marinomed Biotech AG has a diverse portfolio of products, including:

  • Budesolv – A treatment for allergic rhinitis.
  • Tacrosolv – Currently in Phase II clinical trials for inflammatory eye diseases.
  • Carravin – Designed to alleviate nasal congestion.
  • Inhaleen – Targets viral pneumonia.
  • Carragelose – Includes nasal/throat sprays and lozenges for respiratory infections.

Partnerships & History

The company has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. Originally founded in 2006 as Marinomed Biotechnologie GmbH, it rebranded to Marinomed Biotech AG in June 2017.

Frequently Asked Questions

As of 05/20/2025, Marinomed Biotech AG (including the parent company, if applicable) has an estimated market capitalization of $25.07 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Marinomed Biotech AG global market capitalization ranking is approximately 34155 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Austria
Founded 2006
IPO Date n/a
Employees 52
CEO Andreas Grassauer
Sector Healthcare
Industry Biotechnology
Address Hovengasse 25
Korneuburg, Vienna 2100
Austria
Website https://www.marinomed.com
People Also Watch
VRTX
445.19 0.80%
CSL Limited
156.54 0.80%
REGN
610.63 0.80%
KRX-207940
731.22 0.80%